|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Dundr P: Ovarian carcinoma: current
diagnostic principles. Cesk Patol. 46:53–61. 2010.(In Czech).
|
|
3
|
Seidman JD, Ronnett BM and Kurman RJ:
Pathology of borderline (low malignant potential) ovarian tumours.
Best Pract Res Clin Obstet Gynaecol. 16:499–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seidman JD and Kurman RJ: Pathology of
ovarian carcinoma. Hematol Oncol Clin North Am. 17:909–925.
vii2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Westfall D, Roma AA and Silva EG:
High-grade serous carcinoma of the ovary. Ann Diagn Pathol.
13:285–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vang R, Shih Ie M and Kurman RJ: Ovarian
low-grade and high-grade serous carcinoma: pathogenesis,
clinicopathologic and molecular biologic features, and diagnostic
problems. Adv Anat Pathol. 16:267–282. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tarin D: Inappropriate gene expression in
human cancer and its far-reaching biological and clinical
significance. Cancer Metastasis Rev. 31:21–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patterson KI, Brummer T, O’Brien PM and
Daly RJ: Dual-specificity phosphatases: critical regulators with
diverse cellular targets. Biochem J. 418:475–489. 2009.PubMed/NCBI
|
|
9
|
Niculescu MD, Yamamuro Y and Zeisel SH:
Choline availability modulates human neuroblastoma cell
proliferation and alters the methylation of the promoter region of
the cyclin-dependent kinase inhibitor 3 gene. J Neurochem.
89:1252–1259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeh CT, Lu SC, Chen TC, Peng CY and Liaw
YF: Aberrant transcripts of the cyclin-dependent kinase-associated
protein phosphatase in hepatocellular carcinoma. Cancer Res.
60:4697–4700. 2000.PubMed/NCBI
|
|
11
|
Yeh CT, Lu SC, Chao CH and Chao ML:
Abolishment of the interaction between cyclin-dependent kinase 2
and Cdk-associated protein phosphatase by a truncated KAP mutant.
Biochem Biophys Res Commun. 305:311–314. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blum R, Nakdimon I, Goldberg L, et al:
E2F1 identified by promoter and biochemical analysis as a central
target of glioblastoma cell-cycle arrest in response to Ras
inhibition. Int J Cancer. 119:527–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu L, Timmers C, Maiti B, et al: The
E2F1-3 transcription factors are essential for cellular
proliferation. Nature. 414:457–462. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demetrick DJ, Matsumoto S, Hannon GJ, et
al: Chromosomal mapping of the genes for the human cell cycle
proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP
(CDKN3). Cytogenet Cell Genet. 69:190–192. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
MacDermed DM, Khodarev NN, Pitroda SP, et
al: MUC1-associated proliferation signature predicts outcomes in
lung adenocarcinoma patients. BMC Med Genomics. 3:162010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing C, Xie H, Zhou L, et al:
Cyclin-dependent kinase inhibitor 3 is overexpressed in
hepatocellular carcinoma and promotes tumor cell proliferation.
Biochem Biophys Res Commun. 420:29–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor KJ, Sims AH, Liang L, et al:
Dynamic changes in gene expression in vivo predict prognosis of
tamoxifen-treated patients with breast cancer. Breast Cancer Res.
12:R392010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai MW, Chen TC, Pang ST and Yeh CT:
Overexpression of cyclin-dependent kinase-associated protein
phosphatase enhances cell proliferation in renal cancer cells. Urol
Oncol. 30:871–878. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Sun L, Huang J and Jiang M:
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle
computational network between human non-malignancy associated
hepatitis/cirrhosis and hepatocellular carcinoma (HCC)
transformation. Cell Prolif. 44:291–299. 2011. View Article : Google Scholar
|
|
20
|
Felisiak-Golabek A, Dansonka-Mieszkowska
A, Rzepecka I, et al: p19 mRNA and protein expression as new
prognostic factor in ovarian cancer patients. Cancer Biol Ther.
14:973–981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
No JH, Moon JM, Kim K and Kim YB:
Prognostic significance of serum soluble CD163 level in patients
with epithelial ovarian cancer. Gynecol Obstet Invest. 75:263–267.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang L, Wang HY, Li JD, et al: KPNA2
promotes cell proliferation and tumorigenicity in epithelial
ovarian carcinoma through upregulation of c-Myc and downregulation
of FOXO3a. Cell Death Dis. 4:e7452013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bali A, O’Brien PM, Edwards LS, Sutherland
RL, Hacker NF and Henshall SM: Cyclin D1, p53, and p21Waf1/Cip1
expression is predictive of poor clinical outcome in serous
epithelial ovarian cancer. Clin Cancer Res. 10:5168–5177. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee SW, Reimer CL, Fang L, Iruela-Arispe
ML and Aaronson SA: Overexpression of kinase-associated phosphatase
(KAP) in breast and prostate cancer and inhibition of the
transformed phenotype by antisense KAP expression. Mol Cell Biol.
20:1723–1732. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chinami M, Yano Y, Yang X, et al: Binding
of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase
(KAP). Cdk2cyclin A complex enhances the phosphatase activity of
KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of
Cdk2. J Biol Chem. 280:17235–17242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Y, Jiang X, Schoch BS, Carroll RS,
Black PM and Johnson MD: Aberrant splicing of cyclin-dependent
kinase-associated protein phosphatase KAP increases proliferation
and migration in glioblastoma. Cancer Res. 67:130–138. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee J, Sung CO, Lee EJ, et al: Metastasis
of neuroendocrine tumors are characterized by increased cell
proliferation and reduced expression of the ATM gene. PLoS One.
7:e344562012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J, Jackson PK, Kirschner MW and Dutta
A: Separate domains of p21 involved in the inhibition of Cdk kinase
and PCNA. Nature. 374:386–388. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barford D: The mechanism of protein kinase
regulation by protein phosphatases. Biochem Soc Trans. 29:385–391.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johnson LN, De Moliner E, Brown NR, et al:
Structural studies with inhibitors of the cell cycle regulatory
kinase cyclin-dependent protein kinase 2. Pharmacol Ther.
93:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
